Linsitinib (OSI‐906), a dual inhibitor of insulin receptor and IGF1R, for solid tumours has been examined in clinical trials.53 It may be possible to prevent pancreatic cancer by targeting high‐risk groups (eg with a family history) in patients with long‐term type 2 diabetes in the future. Here, INSR is linked to pancreatic neoplasm.